LSE:AZNPharmaceuticals
What Does AstraZeneca (LSE:AZN) News Mean For Its Cancer And Pipeline Growth?
AstraZeneca (LSE:AZN) reports a series of oncology advances, including European Union approval of Enhertu plus pertuzumab as a first-line treatment for HER2-positive metastatic breast cancer.
Tagrisso plus Orpathys delivers positive late-stage results in lung cancer, and AstraZeneca completes a global license agreement for next-generation lung cancer therapy ZEGFROVY.
TEZSPIRE achieves positive phase III results in eosinophilic esophagitis, extending AstraZeneca’s reach in inflammation and...